Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | YAP1 | P46937 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128826 | 0.89 | SLC6A4 (0.49) | SCN9AKDM4EPKMGPR119SLC6A4 | |
| SCHEMBL11957394 | 0.88 | SLC6A4 (0.50) | SCN9AKDM4EPKMGPR119SLC6A4 | |
| SCHEMBL8837960 | 0.88 | SLC6A4 (0.59) | SCN9AKDM4EPKMSLC6A4HTR1A | |
| SCHEMBL12876994 | 0.81 | SLC6A4 (0.52) | SLC6A4HTR1ACYP2D6 | |
| SCHEMBL11949143 | 0.80 | GPR119 (0.45) | SCN9AKDM4EPKMGPR119YAP1 | |
| SCHEMBL11949147 | 0.79 | GPR119 (0.45) | SCN9AKDM4EPKMGPR119SLC6A4 | |
| SCHEMBL8773592 | 0.79 | SLC6A4 (0.47) | SCN9AKDM4EPKMGPR119SLC6A4 | |
| SCHEMBL18310148 | 0.77 | CYP2C9 (0.47) | KDM4EPKMGPR119TLR7 | |
| SCHEMBL11956986 | 0.77 | HTR1A (0.51) | SCN9AKDM4EPKMGPR119SLC6A4 | |
| SCHEMBL13761147 | 0.76 | KDM4E (0.51) | KDM4EPKMGPR119YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011016468-A1 | BENZYL PIPERIDINE COMPOUND | 大日本住友製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |